ReGenX Biosciences

ReGenX Biosciences is a clinical-stage biotechnology company dedicated to improving lives through the development of curative gene therapies. Its core asset is the NAV Technology Platform, a collection of over 100 novel AAV vectors that have become industry standards, powering its own pipeline and over 20 partnered programs, including the commercial therapy Zolgensma®. The company's dual-strategy of internal development and broad licensing has established a significant revenue stream and validates its platform's utility across multiple therapeutic areas.

The proprietary NAV Technology Platform is a collection of over 100 novel adeno-associated virus (AAV) vectors, including NAV AAV8 and AAV9, engineered for targeted gene delivery with specific tissue tropisms and improved therapeutic profiles.

ReGenX competes as a therapeutics developer against other gene therapy and standard-of-care companies in ophthalmology and rare neurology. As a platform, its validated NAV vectors compete with next-generation capsid libraries from firms like 4DMT and Dyno Therapeutics, but its established industry use and IP provide a strong defensive position.